ARCHES 5年生存:恩扎卢胺联合雄激素剥夺治疗转移性激素敏感性前列腺癌
ARCHES 试验事后分析纳入全部 1150 例转移性激素敏感性前列腺癌患者,比较恩扎卢胺联合雄激素剥夺治疗与安慰剂联合雄激素剥夺治疗的 5 年疗效与安全性。中位随访 61.4 个月后,恩扎卢胺组 5 年生存概率为 66%,安慰剂组为 53%(HR 0.70,95%CI 0.58–0.85,p<0.001)。高瘤负荷患者接受恩扎卢胺后生存期延长 36 个月(HR 0.70,95%CI 0.56–0.88),未发现新的安全性信号。
要点
- 恩扎卢胺联合 ADT 使 mHSPC 患者 5 年生存概率提高至 66%(安慰剂组 53%)。
- 高瘤负荷患者接受恩扎卢胺后生存期较安慰剂组延长 36 个月。
- 事后分析的总生存 p 值为名义值,需谨慎解读。
核心结论
- 恩扎卢胺联合雄激素剥夺治疗在转移性激素敏感性前列腺癌患者中显示出长期生存获益,5 年生存概率为 66% 对 53%。
研究设计与样本
- ARCHES 试验(NCT02677896)的事后分析,纳入全部 1150 例随机化患者,数据截止 2024 年 7 月 31 日。
- 患者按 1:1 随机接受恩扎卢胺或安慰剂,均联合雄激素剥夺治疗;首例患者随机化于 2016 年 3 月 21 日。
主要发现
- 中位随访 61.4 个月后,恩扎卢胺组 5 年生存概率为 66%,安慰剂组为 53%(HR 0.70,95%CI 0.58–0.85,p<0.001;校正 HR 0.64,95%CI 0.51–0.75)。
- 高瘤负荷疾病患者接受恩扎卢胺后生存期较安慰剂组延长 36 个月(HR 0.70,95%CI 0.56–0.88)。
- 未观察到新的安全性信号。
关键数值与推荐
- 5 年生存概率:恩扎卢胺组 66%,安慰剂组 53%(中位生存月数两组均未达到)。
- 总生存 HR 0.70(95%CI 0.58–0.85,p<0.001),校正 HR 0.64(95%CI 0.51–0.75)。
- 高瘤负荷患者生存期延长 36 个月,HR 0.70(95%CI 0.56–0.88)。
临床怎么用
- 恩扎卢胺联合雄激素剥夺治疗可作为转移性激素敏感性前列腺癌的长期治疗选择,尤其在高瘤负荷患者中显示生存获益。
- 临床决策时可参考 5 年生存概率数据(66% 对 53%)为患者提供预后预期。
局限性
- 本分析为事后分析,总生存 p 值未经过 alpha 保护,为名义值,应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ARCHES trial (NCT02677896) showed improved radiographic progression-free survival (primary analysis; 2018) and overall survival (prespecified analysis; 2021) with enzalutamide versus placebo, with concomitant androgen-deprivation therapy, in metastatic hormone-sensitive prostate cancer (mHSPC) patients. This post hoc analysis describes 5-yr efficacy and safety for all 1150 randomized patients (data cutoff: July 31, 2024). Patients were randomized 1:1 to receive enzalutamide or placebo (first patient randomized: March 21, 2016). After the primary analysis, ARCHES was unblinded (December 10, 2018); 65% and 32% of patients in the enzalutamide and placebo groups, respectively, enrolled in the open-label extension. After the 61.4-mo median follow-up, 5-yr survival probability was 66% with enzalutamide and 53% with placebo (median months not reached in either group; hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 0.58, 0.85; p < 0.001; adjusted HR: 0.64; 95% CI: 0.51, 0.75). Patients with high-volume disease who received enzalutamide lived 36 mo longer than those who received placebo (HR: 0.70; 95% CI: 0.56, 0.88). No new safety signals emerged. As this was a post hoc, non-alpha protected analysis, the overall survival p value is nominal and should be interpreted cautiously. Overall, this study provides compelling long-term data demonstrating survival benefits with enzalutamide across diverse patient subgroups to guide clinical decision-making and establish prognostic expectations in the mHSPC setting.
引用
- Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol. 2026. PMID: 41633900. doi:10.1016/j.eururo.2025.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。